
|Articles|April 1, 2008
A shot in the dark: Safety, efficacy, research lacking for pediatric medications
Pediatric dermatologist Elaine Siegfried, M.D., says that, about 80 percent of the time, she has to treat patients with drugs that have no FDA-approved indication or have never been formally studied in children.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















